Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Mark Ragosa Sells 12,000 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $41.89, for a total value of $502,680.00. Following the sale, the chief financial officer owned 19,086 shares of the company’s stock, valued at approximately $799,512.54. This trade represents a 38.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Mark Ragosa also recently made the following trade(s):

• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09.
• On Wednesday, November 12th, Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $40.94, for a total value of $814,706.00.
• On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total value of $4,100.00.

Kiniksa Pharmaceuticals International Trading Up 2.3%

KNSA traded up $0.94 on Friday, hitting $42.67. 482,201 shares of the company’s stock were exchanged, compared to its average volume of 651,548. The firm has a market cap of $3.23 billion, a PE ratio of 94.82 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $44.42. The stock has a fifty day moving average of $41.14 and a two-hundred day moving average of $36.21.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the prior year, the company posted ($0.18) EPS. The firm’s revenue was up 61.2% on a year-over-year basis. On average, analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently modified their holdings of the company. Amundi acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $348,000. AQR Capital Management LLC increased its position in Kiniksa Pharmaceuticals International by 149.1% during the first quarter. AQR Capital Management LLC now owns 491,761 shares of the company’s stock worth $10,922,000 after buying an additional 294,319 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after buying an additional 1,002 shares during the last quarter. Millennium Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter worth about $485,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on KNSA. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wedbush reissued an “outperform” rating and set a $48.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, December 2nd. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.